Merck came to Zerbaxa through its $9.5 billion acquisition of Cubist five years ago – but despite the potential new indication sales are a disappointment and well below the blockbuster level of ...

CHMP backs Zerbaxa Merck had some more good news in the last few days after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of its antibiotic Zerbaxa ...

Wall Street analysts forecast that Merck (MRK) will report quarterly earnings ... The consensus among analysts is that 'Sales- Hospital Acute Care- Zerbaxa' will reach $65.05 million.